EN | UA
EN | UA

Help Support

Back

Long-term effect of intralymphatic immunotherapy in allergic rhinitis

Intralymphatic immunotherapy Intralymphatic immunotherapy
Intralymphatic immunotherapy Intralymphatic immunotherapy

A 19-year follow-up study was carried out to explore the long-term effect of intralymphatic immunotherapy (ILIT) on the quality of life and efficacy of the treatment in allergic rhinitis patients.

See All

Key take away

Grass pollen intralymphatic immunotherapy results in long-term significant improvement in rhinitis-related quality of life.

Background

A 19-year follow-up study was carried out to explore the long-term effect of intralymphatic immunotherapy (ILIT) on the quality of life and efficacy of the treatment in allergic rhinitis patients.

Method

Patients who underwent ILIT and subcutaneous immunotherapy (SCIT) treatment, as well as another group of patients who finished SCIT, were enlisted. A conventional Rhinoconjunctivitis Quality of Life Questionnaire and an internal survey tailored specifically for the trial were given to each participant. Off-season and on-season data were collected. Descriptive statistics were used.

Result

The findings of the study indicated the long-term effectiveness of ILIT for treating rhinoconjunctivitis due to sensitization to grass pollen allergens. Notably, 25 (43%) and 29 (54%) of the original 58 and 54 patients who got ILIT or SCIT, respectively, returned the questionnaires for examination. As found, 15 (60%) and 20 (69%) of the ILIT and SCIT patients, respectively, expressed satisfaction with the allergy immunotherapy they got.

Four (16%) and three (11%) of these patients attained complete protection against grass pollen-mediated rhinitis. Any persisting effects were described as modest in both groups. Comparable amounts of medication were taken by the SCIT and ILIT groups. Additionally, 23 (79%) in the SCIT group and 19 (76%) patients in the ILIT group said they were pleased with their allergy immunotherapy.

Conclusion

Nineteen years after treatment, allergic rhinitis patients treated with grass pollen ILIT exhibited considerable improvement in their quality of life, and this impact was comparable to that of SCIT.

Source:

Journal of Allergy and Clinical Immunology

Article:

Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up

Authors:

Yasmin K. Adlany et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: